The autism spectrum disorder management market is anticipated to flourish at an average CAGR of 5.2% between 2023 and 2033. The market is expected to hold a market share of US$ 3.55 billion by 2033 while the market is likely to reach a value of US$ 2.14 billion in 2023.
Autism spectrum disorder can be defined as a neurodevelopment disorder or disability that is caused by rare or common inherited genetic variations, which is fueling the adoption of autism spectrum disorder management lately.
| Attributes | Details |
|---|---|
| Autism Spectrum Disorder Management Market CAGR (2023 to 2033) | 5.2% |
| Autism Spectrum Disorder Management Market Size (2023) | US$ 2.14 billion |
| Autism Spectrum Disorder Management Market Size (2033) | US$ 3.55 billion |
Patients suffering from autism spectrum disorder symptoms face difficulties in social interaction, daily activities, communication, and non-verbal interactions. Billions of people globally are being affected by Autistic Disorder, Asperger Syndrome, and Pervasive
Development disorders and a number of factors are anticipated to contribute to the market’s growth prospects, thereby bolstering a significant growth of the autism spectrum disorder management market during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
It is expected that the autism spectrum disorder management market is likely to have staggering growth and a number of factors are contributing to this rapid expansion of the market.
Rising Awareness About the Treatment: The rising prevalence of autism spectrum disorder or ASD globally, coupled with rising awareness about the condition and the available options for various treatment types of different diseases is the key factor expected to drive the autism spectrum disorder management market.
Growing Investments: The key players in the market are taking research and development initiatives for the launch of effective drugs to manage autistic disorders and are expected to fuel market growth.
Government Funding: Private and government funding is developing the infrastructure for autism spectrum disorder management. It is identified that there is a rise in the number of organizations overcoming communication problems and social challenges. NGO activities are anticipated to rise for making parents aware of the disorders, which will boost the growth of the market.
Although there are a number of growth factors prevailing in the market, it is identified that some aspects are likely to inhibit the expansion of the market size of autism spectrum disorder management.
High cost: It is witnessed that the treatment of autism spectrum disorder requires a high cost of treatment and diagnosis, which is expected to hinder the growth of the market.
Lack of Approved Drugs: It is identified that currently no drug can cure autism spectrum disorder or any of its associated core symptoms despite the increase in the need for effective clinical and drug trials for ASD.
It is witnessed that there are fundamental weaknesses in the methods, conceptual models in clinical translation research, and knowledge gaps, which will curb the growth in the coming years.
Principal Consultant
| Countries | Revenue Share % (2022) |
|---|---|
| United States | 37.6% |
| Germany | 7.6% |
| Japan | 3.2% |
| North America | 43.1% |
| Europe | 32.7% |
| Countries | CAGR % (2023 to 2033) |
|---|---|
| China | 6.3% |
| India | 5.2% |
| United Kingdom | 3.7% |
| Australia | 4.6% |
| Attributes | Details |
|---|---|
| Region | North America |
| Market Share | It is projected that North America is likely to hold the largest share of the autism spectrum disorder management market. Market Share Holding in 2022: 43.1% |
| Factors Responsible | The factors attributing to growth are:
|
| Attributes | Details |
|---|---|
| Region | Europe |
| Market Share | Europe is projected to hold the second-largest share of the autism spectrum disorder management market after North America and is likely to have substantial growth in the coming years. Market Share Holding in 2022: 32.7% |
| Factors Responsible | The factors attributing to expansion are:
|
| Category | By Indication Type |
|---|---|
| Leading Segment | Autistic Disorder |
| Market Share | 43.70% |
| Category | By Treatment Type |
|---|---|
| Leading Segment | Behavioral Approaches |
| Market Share | 32.40% |
Based on indication type, the autistic disorder segment leads the market as it held a market share of 43.70% in 2022. The treatment type category is dominated by the behavioral approaches segment as it held a market share of 32.40% in 2022.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The start-up companies are intensifying their focus on frequent innovations and indulging themselves in mergers and acquisitions to develop cost-effective, yet high-performance autism spectrum disorder management solutions.
Three Start-Ups to Watch for in the ASD Management Market
Key Take of the Biggies in the Autism Spectrum Disorder Management Market
The key players in the market are making efforts and continually indulging in joint ventures, collaboration & mergers amongst themselves to launch novel products for the treatment of autism by research institutes, and cost-effective treatment for the end-users.
Recent Developments
Some of the recent developments are:
The market is estimated to secure US$ 2.14 billion in 2023.
The rising prevalence of autism spectrum disorder or ASD globally and the research and development initiatives to launch effective drugs drive the market.
The high cost of treatment and diagnosis and the need for approved drugs restrain market growth.
The United States may witness significant growth in the market.
The United States, Japan, and China dominate the global market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033 5.3.1. Autistic Disorder 5.3.2. Asperger Syndrome 5.3.3. PDD-NOS 5.3.4. Other Pervasive Developmental Disorders 5.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 6.3.1. Behavioural Approaches 6.3.2. Early Intervention 6.3.3. Medication 6.3.4. Others 6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End-User , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User , 2023 to 2033 7.3.1. Hospitals 7.3.2. Education Counsellor Center 7.3.3. Others 7.4. Y-o-Y Growth Trend Analysis By End-User , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End-User , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA. 9.2.1.2. Canada 9.2.2. By Product Type 9.2.3. By Treatment 9.2.4. By End-User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product Type 9.3.3. By Treatment 9.3.4. By End-User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Product Type 10.2.3. By Treatment 10.2.4. By End-User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product Type 10.3.3. By Treatment 10.3.4. By End-User 10.4. Key Takeaways 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK. 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Product Type 11.2.3. By Treatment 11.2.4. By End-User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product Type 11.3.3. By Treatment 11.3.4. By End-User 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Product Type 12.2.3. By Treatment 12.2.4. By End-User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product Type 12.3.3. By Treatment 12.3.4. By End-User 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Product Type 13.2.3. By Treatment 13.2.4. By End-User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product Type 13.3.3. By Treatment 13.3.4. By End-User 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Product Type 14.2.3. By Treatment 14.2.4. By End-User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product Type 14.3.3. By Treatment 14.3.4. By End-User 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Product Type 15.2.3. By Treatment 15.2.4. By End-User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Product Type 15.3.3. By Treatment 15.3.4. By End-User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA. 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Product Type 16.1.2.2. By Treatment 16.1.2.3. By End-User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Product Type 16.2.2.2. By Treatment 16.2.2.3. By End-User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Product Type 16.3.2.2. By Treatment 16.3.2.3. By End-User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Product Type 16.4.2.2. By Treatment 16.4.2.3. By End-User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Product Type 16.5.2.2. By Treatment 16.5.2.3. By End-User 16.6. UK. 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Product Type 16.6.2.2. By Treatment 16.6.2.3. By End-User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Product Type 16.7.2.2. By Treatment 16.7.2.3. By End-User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Product Type 16.8.2.2. By Treatment 16.8.2.3. By End-User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Product Type 16.9.2.2. By Treatment 16.9.2.3. By End-User 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Product Type 16.10.2.2. By Treatment 16.10.2.3. By End-User 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Product Type 16.11.2.2. By Treatment 16.11.2.3. By End-User 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Product Type 16.12.2.2. By Treatment 16.12.2.3. By End-User 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Product Type 16.13.2.2. By Treatment 16.13.2.3. By End-User 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Product Type 16.14.2.2. By Treatment 16.14.2.3. By End-User 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Product Type 16.15.2.2. By Treatment 16.15.2.3. By End-User 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Product Type 16.16.2.2. By Treatment 16.16.2.3. By End-User 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Product Type 16.17.2.2. By Treatment 16.17.2.3. By End-User 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Product Type 16.18.2.2. By Treatment 16.18.2.3. By End-User 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Product Type 16.19.2.2. By Treatment 16.19.2.3. By End-User 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Product Type 16.20.2.2. By Treatment 16.20.2.3. By End-User 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Product Type 16.21.2.2. By Treatment 16.21.2.3. By End-User 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2022 16.22.2.1. By Product Type 16.22.2.2. By Treatment 16.22.2.3. By End-User 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2022 16.23.2.1. By Product Type 16.23.2.2. By Treatment 16.23.2.3. By End-User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Product Type 17.3.3. By Treatment 17.3.4. By End-User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Curemark, LLC 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Alembic Pharmaceuticals Limited 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Yamo Pharmaceuticals 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. PaxMedica 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. F. Hoffmann-La Roche Ltd 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Aurobindo Pharma Ltd. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Otsuka Holdings Co. Ltd. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Janssen Pharmaceuticals, Inc. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Teva Pharmaceutical Industries Ltd. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. H. Lundbeck A/S 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Healthcare
March 2022
REP-GB-14407
January 2023
330 pages
Explore Healthcare Insights
View Reports
Autism Spectrum Disorder Management Market
